News
Media
Conferences
Publications
Events
CME/CE
Resources
Career Center
Subscribe

|Videos|December 8, 2022

Bispecifics in Development for the Treatment of R/R MM

Author(s)Peter Voorhees, MD, Cristina Gasparetto, MD, Cindy Varga, MD

Dr Tuchman highlights exciting bispecific agents in investigation for the treatment of relapsed/refractory multiple myeloma.

Episodes in this series

EP. 1 Patient Profile: A 59-Year-Old Man with Transplant Eligible Newly-Diagnosed Multiple Myeloma (NDMM)

EP. 2 Available Induction Regimen Options for Patients with Transplant-Eligible NDMM

EP. 2 Available Induction Regimen Options for Patients with Transplant-Eligible NDMM

Recap: Recent Research in Multiple Myeloma

EP. 3 Recap: Recent Research in Multiple Myeloma

EP. 4 Evaluating MRD-Guided Therapy in Patients with NDMM

EP. 4 Evaluating MRD-Guided Therapy in Patients with NDMM

EP. 5 Assessing Response and Duration of Treatment in Transplant-Eligible NDMM

EP. 5 Assessing Response and Duration of Treatment in Transplant-Eligible NDMM

EP. 6 Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma

EP. 6 Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma

EP. 7 Selecting Frontline Treatment Regimens for Transplant-Ineligible MM

EP. 7 Selecting Frontline Treatment Regimens for Transplant-Ineligible MM

EP. 8 Data Updates in Transplant Ineligible NDMM

EP. 8 Data Updates in Transplant Ineligible NDMM

EP. 9 Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM

EP. 9 Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM

EP. 10 Defining Frail Patients in Multiple Myeloma

EP. 10 Defining Frail Patients in Multiple Myeloma

EP. 11 Treatment Options for Patients with Relapsed Multiple Myeloma

EP. 11 Treatment Options for Patients with Relapsed Multiple Myeloma

EP. 12 Bispecifics in Development for the Treatment of R/R MM

EP. 12 Bispecifics in Development for the Treatment of R/R MM

$EP. 13 Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM$

EP. 13 Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related Content

Ajay K. Nooka, MD, MPH, FACP, discusses how results from the MonumenTAL-6 trial build upon prior studies assessing bispecific antibodies in multiple myeloma.

The Lowest-Ever Hazard Ratio in Multiple Myeloma Bispecific Trials?

August 6th 2026

Adam D. Cohen, MD, said that more data are necessary to help determine how cevostamab can be sequenced with other T-cell–directed therapies.

Cevostamab Trial Validates FcRH5 as a Multiple Myeloma Target

ByAdam D. Cohen, MD

August 5th 2026

Adam D. Cohen, MD, says patients with deep responses to cevostamab could stop therapy and stay in remission for years.

Fixed-Duration Cevostamab Yields Durable Responses Off Therapy

ByAdam D. Cohen, MD

August 4th 2026

Phase 1 trial data for cevostamab in multiple myeloma validate fixed-duration therapy as a “good concept,” according to Adam D. Cohen, MD.

How Effective is Fixed-Duration Cevostamab in Multiple Myeloma?

August 4th 2026

Ajay K. Nooka, MD, MPH, FACP, says multiple myeloma treatment is entering an immunotherapy deluge, with more data on bispecifics ahead.

The Beginning of the “Immunotherapy Deluge” in Multiple Myeloma

ByAjay K. Nooka, MD, MPH, FACP

August 3rd 2026

Latest CME

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Kansas Society of Clinical Oncology

Aditya Bardia, MD, MPH, FASCO; Bachar Samra, MD

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Breaking Down the Rationale for Targeting TROP2 in TNBC

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Missouri Oncology Society

Sara A. Hurvitz, MD, FACP; Shaina Rozell, MD, MPH

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2– Metastatic Breast Cancer | Louisiana Oncology Society

Kamel Abou Hussein, MD

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Arizona

Community Oncology Connections™: Advancing Precision Testing and HER2-Targeted Care for Gastroesophageal Adenocarcinoma – Arizona

Syma Iqbal, MD; Benjamin Scheier, MD

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Kansas Society of Clinical Oncology

Kansas Society of Clinical Oncology

1 Session is Available!

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

Show Me Your Care Plan!™ Navigating ADC Therapies: Oncology Nursing Strategies for Optimal Patient Management

August 24, 2026

Optimizing Treatment for Biliary Tract Cancers

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Wisconsin Association of Hematology and Oncology

Kurt C. Demel, MD, MBA; Sara A. Hurvitz, MD, FACP

25th Annual International Congress on the Future of Breast Cancer® West

25th Annual International Congress on the Future of Breast Cancer® West

Sara A. Hurvitz, MD, FACP; Joyce O’Shaughnessy, MD

25th Annual International Congress on the Future of Breast Cancer® East

25th Annual International Congress on the Future of Breast Cancer® East

Joyce O’Shaughnessy, MD

Arizona Clinical Oncology Society

Arizona Clinical Oncology Society

1 Sessions is Available!

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Arkansas Association of Cancer Professionals

Kamel Abou Hussein, MD; Yelda Nouri, MD

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Community Oncology Connections™: Monotherapies vs Combinations – Navigating Oral SERDs and Targeted Combination Strategies in HR+/HER2- Metastatic Breast Cancer | Rhode Island Oncology Society

Aditya Bardia, MD, MPH, FASCO; Benjamin Scheier, MD

Radioligand Therapy 101: The Science Behind the Strategy

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

In-Person + Virtual Event

Medical Crossfire®: ADCs and Bispecifics in Lung Cancer – Hype, Hope, or a New Standard of Care?

September 12, 2026

Wisconsin Association of Hematology and Oncology

Wisconsin Association of Hematology and Oncology

2 Sessions are Available!

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

𝘔𝘌𝘛 Alterations in NSCLC: Applying Diagnostic Advances and Targeted Therapies in a New Era of Treatment

Jonathan Goldman, MD; Sanja Dacic, MD, PhD; Deborah Doroshow, MD, PhD; Anne S. Tsao, MD, MBA

Tennessee Oncology Practice Society

Tennessee Oncology Practice Society

2 Session are Available!

Washington State Medical Oncology Society

Washington State Medical Oncology Society

2 Sessions are Available!

Colorado Oncology Society

Colorado Oncology Society

2 Sessions are Available!

27th Annual International Lung Cancer Congress®

27th Annual International Lung Cancer Congress®

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Satellite Symposia at the Annual Radiation Oncology Meeting

In-Person + Virtual Event

Satellite Symposia at the Annual Radiation Oncology Meeting

September 26-30, 2026

Minnesota Society of Clinical Oncology

Minnesota Society of Clinical Oncology

3 Sessions are Available!

North Carolina Oncology Association

North Carolina Oncology Association

3 Sessions are Available!

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Enhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment Strategies

Ana Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACP

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

Michelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPO

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Personalized Approaches in NSCLC: Early Detection, Molecular Testing, and Targeted Therapies

Charu Aggarwal, MD, MPH, FASCO; Zofia Piotrowska, MD, MHS

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Community Practice Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer—From Innovation to Practice

Jacob Sands, MD; Anne Chiang, MD, PhD

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Cases and Conversations™: Transforming Small Cell Lung Cancer Treatment Through Emerging Evidence and Expert Insights

Charles M. Rudin, MD, PhD; Anne Chiang, MD, PhD, FASCO; Jacob M. Sands, MD

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Biomarker Testing in HER2+ GEA: Diagnosis and Treatment Implications

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rutika Mehta, MD, MPH

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Hot Seat: Converging Lines in the Management of RAS-Altered Cancers

Shubham Pant, MD, MBBS; Alison Schram, MD; Helena Yu, MD

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Revolutionizing TGCT Care with Multidisciplinary Perspectives and Cutting-Edge Targeted Therapies

Mark Agulnik, MD; Lee M. Zuckerman, MD

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Hope S. Rugo, MD; Alison K. Conlin, MD; Marleen Kok, MD, PhD; Heather McArthur, MD, MPH

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Sara A. Hurvitz, MD, FACP; Rena Callahan, MD; Michelle Melisko, MD; Paolo Tarantino, MD, PhD

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

The Rise of Novel HER2-Targeting Therapies in GEA: Mechanisms and Clinical Data

Rahul Gosain, MD, MBA; Rohit Gosain, MD

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Beyond Primary End Points: Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer

Seth A. Wander, MD, PhD; Marla D. Lipsyc-Sharf, MD

Diagnosis and Management of TGCT

Diagnosis and Management of TGCT

Mark Agulnik, MD; Lee M. Zuckerman, MD

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Cases & Conversations™: Unmasking Epithelioid Sarcoma – Enhancing Early Diagnosis and Multidisciplinary Care

Mark Agulnik, MD; Mrinal M. Gounder, MD; Sandra D’Angelo, MD; Sujana Movva, MD

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Real-World Insights on Advances in the Management of Myeloproliferative Neoplasms: How the Experts Apply the Latest Developments to Clinical Practice

Naveen Pemmaraju, MD; Shannon Elf, PhD; Angela Fleischman, MD, PhD; Bethan Psaila, MD

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Case-based Simulation

SimulatEd™: A Roadmap to Personalized Care Plans and Shared Decision-Making in Low-Grade Serous Ovarian Cancer

Rachel N. Grisham, MD

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

Expert Illustrations & Commentaries: Translating the Science of Bispecific Antibodies in Solid Tumors – From Mechanisms to Emerging Data

John V. Heymach, MD, PhD; Anne S. Tsao, MD, MBA, FASCO, FACHE

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Tumor Board™: Navigating a New Era of Innovation and Expanding Options in NMIBC

Archan Khandekar, MD; Wassim Kassouf, MD, CM, FRCSC; Jen-Jane Liu, MD

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

“D” is for Diagnosis: Decoding a Difficult Thoracic Malignancy—Piecing Together a Rare Diagnosis, Preparing for Tomorrow’s Treatments

Aakash Desai, MD, MPH; Ibiayi Dagogo-Jack, MD, FASCO; Patrick Forde, MD, PhD

Trending on CancerNetwork

FDA Approves RP1/Nivolumab for Progression on Anti–PD-1 Therapy in Melanoma

Why Earlier CAR T-Cell Therapy May Benefit Patients With Multiple Myeloma

What Does an End-of-Life Doula Do for Patients With Cancer?

GLP-1 Receptor Agonists and Cancer: Renewed Momentum for Metabo-Oncology

Why CAR T-Cell Therapy Should Precede Bispecifics in Multiple Myeloma